Internal Med

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Reich K et al. – Patients with moderate–to–severe psoriasis entered this trial with serious PRO impairment. At week 12, etanercept 50 mg QW provided significant QoL improvements compared with placebo. After 24 weeks of etanercept, the patients' serious PRO impairment had largely abated.


Today in Clinical Pharmacology...keeping you current

Novel Therapies for Pemphigus Vulgaris: An Overview
Drugs & Aging, 09/21/09

Antithrombotic medication for stroke prevention
Expert Review of Cardiovascular Therapy , 10/20/09

Osteonecrosis of the jaw correlated to bisphosphonate therapy in non-oncologic patients: Clinicopathological features of 24 patients
Journal of Rheumatology, 11/09/09

Today in Dermatology...keeping you current

Novel Therapies for Pemphigus Vulgaris: An Overview
Drugs & Aging, 09/21/09

Skin fusion on the fingers and toes of an adolescent girl
The Clinical Advisor, 09/10/09

Erysipeloid: a review
Clinical and Experimental Dermatology, 09/18/09


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Sponsor

Send this Summary to a Colleague

Enter email address